Table 3.
Number and percentages of the noADMCI-noEEA and noADMCI-EEA patients assuming the selective serotonin reuptake inhibitors (SSRIs), selective serotonin and noradrenaline reuptake inhibitors (SNRIs), benzodiazepines (BZDs), non-benzodiazepines GABA acting agent (No BZDs), and acetylcholinesterase inhibitors (AChEIs).
| Drugs | noADMCI-noEEA | noADMCI-EEA | Fisher test | ||
|---|---|---|---|---|---|
| N | (%) | N | (%) | ||
| Selective serotonin reuptake inhibitors (SSRIs) | 8 | 42.1 | 6 | 46.2 | p = 0.9 |
| Selective serotonin and noradrenaline reuptake inhibitors (SNRIs) | 1 | 5.3 | 0 | 0 | p = 0.9 |
| Benzodiazepine (BZD) | 4 | 21.2 | 3 | 23.1 | p = 0.9 |
| Non benzodiazepine GABA acting agent (No BZD) | 1 | 5.3 | 0 | 0 | p = 0.9 |
| Acetylcholinesterase inhibitor (AChEI) | 2 | 10.5 | 1 | 0 | p = 0.9 |
| All drugs | 10 | 52.6 | 7 | 53.8 | p = 0.9 |
The results of the presence or absence of statistically significant differences (Fisher test, p < 0.05 corrected) between the noADMCI-noEEA and noADMCI-EEA groups. The consumption of those drugs is also reported. All ADMCI patients had the information relative to the drug consumption available. noADMCI-noEEA, patients with mild cognitive impairment not due to Alzheimer's disease and without epileptiform EEG activity; noADMCI-EEA, patients with mild cognitive impairment not due to Alzheimer's disease and epileptiform EEG activity. No significant difference was observed between the two noADMCI groups even when a marginal threshold of p < 0.05 uncorrected was used.